Gilead Sciences / 吉利德

Gilead Sciences / 吉利德 appears in vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 as a contrast case: the episode praises a long-acting HIV-prevention result while treating the company’s oncology bets as more troubled. The source says a twice-yearly HIV prevention drug showed complete prevention in a women’s trial, while Gilead’s CD47, TIGIT, and ADC-related oncology investments had disappointed.

The page keeps the episode’s distinction intact: Gilead is not judged as simply strong or weak, but as a company whose antiviral excellence and oncology dealmaking record can diverge.

Connections

• Long-Acting HIV Prevention - main product-direction concept added by the episode.
• ADC Engineering Optimization and Dual-Payload ADC - oncology-adjacent fields where the source discusses deal risk and technical optimism.
• Multinational Pharma Patent-Cliff Anxiety - broader big-pharma pipeline pressure context.